We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Amgen (AMGN - Free Report) closed at $189.92 in the latest trading session, marking a +1.53% move from the prior day. This change outpaced the S&P 500's 0.56% gain on the day. Elsewhere, the Dow gained 0.76%, while the tech-heavy Nasdaq lost 0.38%.
Heading into today, shares of the world's largest biotech drugmaker had lost 8.07% over the past month, lagging the Medical sector's loss of 6.31% and the S&P 500's loss of 6.76% in that time.
Wall Street will be looking for positivity from AMGN as it approaches its next earnings report date. This is expected to be February 7, 2019. On that day, AMGN is projected to report earnings of $3.25 per share, which would represent year-over-year growth of 12.46%. Meanwhile, our latest consensus estimate is calling for revenue of $5.86 billion, up 1% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $14.18 per share and revenue of $23.34 billion. These totals would mark changes of +12.72% and +2.15%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for AMGN. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.61% higher within the past month. AMGN is currently a Zacks Rank #3 (Hold).
Digging into valuation, AMGN currently has a Forward P/E ratio of 13.19. Its industry sports an average Forward P/E of 27.63, so we one might conclude that AMGN is trading at a discount comparatively.
We can also see that AMGN currently has a PEG ratio of 1.95. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. AMGN's industry had an average PEG ratio of 1.84 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 87, which puts it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
Amgen (AMGN - Free Report) closed at $189.92 in the latest trading session, marking a +1.53% move from the prior day. This change outpaced the S&P 500's 0.56% gain on the day. Elsewhere, the Dow gained 0.76%, while the tech-heavy Nasdaq lost 0.38%.
Heading into today, shares of the world's largest biotech drugmaker had lost 8.07% over the past month, lagging the Medical sector's loss of 6.31% and the S&P 500's loss of 6.76% in that time.
Wall Street will be looking for positivity from AMGN as it approaches its next earnings report date. This is expected to be February 7, 2019. On that day, AMGN is projected to report earnings of $3.25 per share, which would represent year-over-year growth of 12.46%. Meanwhile, our latest consensus estimate is calling for revenue of $5.86 billion, up 1% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $14.18 per share and revenue of $23.34 billion. These totals would mark changes of +12.72% and +2.15%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for AMGN. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.61% higher within the past month. AMGN is currently a Zacks Rank #3 (Hold).
Digging into valuation, AMGN currently has a Forward P/E ratio of 13.19. Its industry sports an average Forward P/E of 27.63, so we one might conclude that AMGN is trading at a discount comparatively.
We can also see that AMGN currently has a PEG ratio of 1.95. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. AMGN's industry had an average PEG ratio of 1.84 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 87, which puts it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.